Celecoxib/tramadol

Celecoxib/tramadol
Combination of
CelecoxibNonsteroidal anti-inflammatory drug (NSAID)
Tramadol hydrochlorideOpioid agonist
Clinical data
Trade namesSeglentis
Other namesE-58425
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]

Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]

References

  1. ^ a b c "Seglentis- celecoxib and tramadol hydrochloride tablet". DailyMed. Retrieved 8 January 2022.
  2. ^ "Seglentis: FDA-Approved Drugs". U.S. Food and Drug Administration. Archived from the original on 19 October 2021. Retrieved 18 October 2021.
  3. ^ "Esteve Announces FDA Approval Of A Novel Co-Crystal Form Of Celecoxib And Tramadol For The Management Of Acute Pain". Esteve (Press release). 15 October 2021. Retrieved 18 October 2021.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.